Hayden E. Klein

Version 5 of “COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases" includes updated recommendations that differentiate supplemental and booster doses for people with rheumatic and musculoskeletal diseases (RMDs).

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses delayed booster vaccines and potential fourth doses for people who are immunosuppressed.

Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the background and results of the TOPAZ-1 study.

Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, summarizes the benefits and safety findings discovered in the HIMALAYA study.

Research showed that younger and nonfrail patients with COVID-19 were more likely to be put on a ventilator, while patients with frailty and older age had a higher risk of in-hospital and in-ICU mortality.

Patients with rheumatoid arthritis (RA) who used 3 or more targeted therapies, but not Janus kinase inhibitors, were at greater risk of developing herpes zoster, according to findings from a Korean study.

Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, discusses his study comparing rates of lower extremity amputations in US veterans with and without gout, using data from the national Veterans Health Administration.

Researchers have discovered a highly virulent HIV-1 variant in the Netherlands that causes immune system strength to decline twice as fast vs other HIV strains.

Geoffrey Boyce, CEO of Array Behavioral Care, discusses Array AtHome’s telebehavioral health services, which are now available to approximately 5 million Humana Medicare Advantage members.

COVID-19 vaccine uptake among people living with HIV was associated with older age, more years living with HIV, higher education level, and higher perceived COVID-19 vulnerability.

Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the design of the HIMALAYA study, including the dosing strategy used.

A study found that antibody response against COVID-19 decreased by 2.8 times between months 1 and 6 post vaccination among people with rheumatic and musculoskeletal disease.

The review discussed the roles of sex, ancestry, senescence, and aging in the development of nontuberculous mycobacterial pulmonary disease.

Speakers at the Greater Philadelphia Business Coalition on Health (GPBCH) discussed data on lifestyles, economic trends, and presented real-life examples of obesity treatment, as well as a benefit design for obesity.

After analyzing past studies and classification criteria, authors found multiple factors that could be implemented into the current rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) tests for a more specific rheumatoid arthritis (RA) classification.

Women in the study were 3 times more likely to be affected by rheumatoid arthritis (RA) and nearly 4 times more likely to develop hypothyroidism, compared with men.

Implementing evidence-based guidelines (EBGs) resulted in a 17.3% reduction in anaphylaxis-related hospitalizations among children.

With no existing respiratory syncytial virus (RSV) vaccine yet, researchers found that a vaccine comparable with the influenza vaccine could prevent tens of thousands of hospitalizations and deaths per year.

A mother in her early 30s received her HIV-1 diagnosis only after her child received their diagnosis of both HIV-1 and Pneumocystis jirovecii pneumonia at age 28 weeks.

Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology.

Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, explains why low-value care still exists and how the COVID-19 pandemic has affected the issue.

A study found that frailty reduced the likelihood of comprehensive disease control achievement by patients with rheumatoid arthritis (RA) being treated with a biologic agent.

Neither adalimumab nor secukinumab substantially affected a patient’s immune response to the Pfizer COVID-19 vaccine.

Researchers found that fully vaccinated people with HIV have a 41% higher risk of COVID-19 breakthrough infection compared with people without HIV.

Daridorexant belongs to a class of drugs known as a dual orexin receptor antagonists.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, describes the shifts in COVID-19 recommendations for patients with cancer and those receiving CAR T-cell therapy.

The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses the National Comprehensive Cancer Network's (NCCN) preference for mRNA vaccines and how they work differently.

Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, describes the main challenges to identifying, measuring, and reducing use of low-value care and the granular data needed to solve these challenges.

Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.